Annie Yoshiyama
Net worth: 258 995 $ as of 29/06/2026
Net worth: 258 995 $ as of 29/06/2026
Annie Yoshiyama currently works at Allogene Therapeutics, Inc., as Senior Vice President & Controller from 2024.
Ms. Yoshiyama also formerly worked at Tricida, Inc., as Chief Accounting Officer & Vice President-Finance, Dolby Laboratories, Inc., as Senior Financial Reporting from 2008 to 2018, and AN2 Therapeutics, Inc., as Vice President-Finance & Controller from 2023 to 2024.
Ms. Yoshiyama received her undergraduate degree and graduate degree from the University of Southern California.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 20/04/2026 | 124,517 ( 0.04% ) | 258 995 $ | 29/06/2026 |
| Companies | Position | Start |
|---|---|---|
| ALLOGENE THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 04/06/2024 |
| Companies | Position | End |
|---|---|---|
| AN2 THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 29/02/2024 |
| TRICIDA, INC. | Comptroller/Controller/Auditor | 31/08/2023 |
| DOLBY LABORATORIES, INC. | Corporate Officer/Principal | 31/05/2018 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Tricida, Inc.
Tricida, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical preparation products | Health Technology |
University of Southern California
University of Southern California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dolby Laboratories, Inc.
Dolby Laboratories, Inc. Packaged SoftwareTechnology Services Develops audio and imaging technologies and products for cinema, television, broadcast & entertainment industries | Technology Services |
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage immuno-oncology | Health Technology |
AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics | Health Technology |
Select your edition
All financial news and data tailored to specific country editions